- Previous Rank-
- Revenue 3 Yr Annual Growth Rate18%
- Revenue 3 Yr Growth Rank88
- EPS 3 Yr Annual Growth Rate83%
- EPS 3 Yr Growth Rank12
- Total Return 3 Yr Annual Rate2%
- Total Return 3 Yr Rank92
Jazz, which became an Irish company after its merger with Azur Pharma in 2012, has a drug portfolio focused on narcolepsy and hematology.
Looking for leads, investment insights, or competitive intelligence?Buy Now
Company Information
| Location | Dublin, Ireland |
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Current Streak | 1 |
| Years on List | 2 |
| CEO | Bruce Cozadd |
| Website | http://www.jazzpharma.com |
Revenue and net income for the four quarters ended on or before April 30, 2017. Total return for the period ended June 30, 2017.
Revenue, Net Income
| Revenue past four quarters ($M) | $1,528 |
| Net Income past four quarters ($M) | $408 |
Growth Rates and Ranks
| Revenue 3 Yr Growth Rank | 88 |
| Revenue 3 Yr Annual Growth Rate | 18% |
| EPS 3 Yr Growth Rank | 12 |
| EPS 3 Yr Annual Growth Rate | 83% |
| Total Return 3 Yr Rank | 92 |
| Total Return 3 Yr Annual Rate | 2% |
| Beat S&P 500 (9.6%) | no |
| P/E Ratio | 21 |